{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:39:58Z","timestamp":1792427998976,"version":"4.5.0"},"reference-count":257,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jaci.2025.04.016","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:40:08Z","timestamp":1745325608000},"page":"237-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Converging paths toward unified therapeutic approaches in atopic dermatitis, vitiligo, and alopecia areata"],"prefix":"10.1016","volume":"156","author":[{"given":"Lea","family":"Tordjman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla D.","family":"Mashoudy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Czarnowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2025.04.016_bib1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13223-021-00597-4","article-title":"Atopic dermatitis and risk of autoimmune diseases: a systematic review and meta-analysis","volume":"17","author":"Lu","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaad.2010.08.032","article-title":"Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study","volume":"65","author":"Chu","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib3","doi-asserted-by":"crossref","unstructured":"Muntyanu A, Gabrielli S, Donovan J, Gooderham M, Guenther L, Hanna S, et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity [published online ahead of print January 27, 2023]. J Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.18926.","DOI":"10.1111\/jdv.18926"},{"key":"10.1016\/j.jaci.2025.04.016_bib4","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s13555-024-01187-z","article-title":"Health-related quality of life burden among adults with vitiligo: relationship to disease severity and disease location","volume":"14","author":"Rosmarin","year":"2024","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2025.04.016_bib5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrmicro.2017.157","article-title":"The human skin microbiome","volume":"16","author":"Byrd","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jaci.2025.04.016_bib8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","article-title":"The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment","volume":"20","author":"Facheris","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2025.04.016_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2025.04.016_bib12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2025.04.016_bib13","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJMoa0908547","article-title":"Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo","volume":"362","author":"Jin","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.04.016_bib14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ng1767","article-title":"Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis","volume":"38","author":"Palmer","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2025.04.016_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/bjd\/ljad339","article-title":"Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study","volume":"190","author":"Tian","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib16","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.det.2017.02.002","article-title":"Public health burden and epidemiology of atopic dermatitis","volume":"35","author":"Silverberg","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2025.04.016_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2010.251","article-title":"Eczema prevalence in the United States: data from the 2003 National Survey of Children\u2019s Health","volume":"131","author":"Shaw","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2021.4724","article-title":"Prevalence of vitiligo among adults in the United States","volume":"158","author":"Gandhi","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","article-title":"Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljae266.073","article-title":"Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study [Abstract 699]","volume":"191","author":"Mostaghimi","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib22","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1007\/s12325-024-02875-0","article-title":"Epidemiology and treatment patterns of patients with vitiligo: a real-world analysis","volume":"41","author":"Ramot","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaci.2025.04.016_bib23","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40257-018-0383-4","article-title":"Major comorbidities of atopic dermatitis: beyond allergic disorders","volume":"19","author":"Paller","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib24","article-title":"Association of atopic dermatitis with autoimmune diseases: a bidirectional and multivariable two-sample Mendelian randomization study","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib25","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2016.08.047","article-title":"Autoimmune diseases in adults with atopic dermatitis","volume":"76","author":"Andersen","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2009.04.031","article-title":"History of atopy or autoimmunity increases risk of alopecia areata","volume":"61","author":"Barahmani","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib27","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.2147\/JIR.S331579","article-title":"Prevalence and risk factors associated with the occurrence of autoimmune diseases in patients with alopecia areata","volume":"14","author":"Chanprapaph","year":"2021","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.jaci.2025.04.016_bib28","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/all.13128","article-title":"Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses\u2019 Health Study 2","volume":"72","author":"Drucker","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.04.016_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/derm.2023.0114","article-title":"Bilateral association between atopic dermatitis\u00ae and alopecia areata: a systematic review and meta-analysis","volume":"35","author":"Sun","year":"2024","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaci.2025.04.016_bib30","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","article-title":"Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis","volume":"151","author":"Mohan","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib31","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3346\/jkms.2012.27.7.799","article-title":"Clinical characteristics and prognostic factors in early-onset alopecia totalis and alopecia universalis","volume":"27","author":"Cho","year":"2012","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jaci.2025.04.016_bib32","doi-asserted-by":"crossref","first-page":"722","DOI":"10.5021\/ad.2014.26.6.722","article-title":"Differences in comorbidity profiles between early-onset and late-onset alopecia areata patients: a retrospective study of 871 Korean patients","volume":"26","author":"Lee","year":"2014","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib33","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1468-3083.2006.01676.x","article-title":"Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history","volume":"20","author":"Goh","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2025.04.016_bib34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jid.2022.10.021","article-title":"Comorbidities in patients with vitiligo: a systematic review and meta-analysis","volume":"143","author":"Lee","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib35","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.21037\/apm-21-1738","article-title":"Prevalence of vitiligo and associated comorbidities in adults in Shanghai, China: a community-based, cross-sectional survey","volume":"10","author":"Tang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.jaci.2025.04.016_bib36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000354607","article-title":"Comorbidities associated with vitiligo: a ten-year retrospective study","volume":"227","author":"Sheth","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.jaci.2025.04.016_bib37","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1016\/S2468-2667(24)00026-4","article-title":"Estimating the burden of vitiligo: a systematic review and modelling study","volume":"9","author":"Akl","year":"2024","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.jaci.2025.04.016_bib38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13223-024-00892-w","article-title":"Genetic links between atopy, allergy, and alopecia areata: insights from a Mendelian randomization study","volume":"20","author":"Xu","year":"2024","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib39","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2023.05.023","article-title":"The impact of atopic dermatitis on alopecia areata: a 2-sample Mendelian randomization study","volume":"89","author":"O\u2019Hagan","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib40","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00403-024-03469-0","article-title":"Unraveling the genetic relationship between alopecia areata and vitiligo","volume":"316","author":"Zhou","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2025.04.016_bib41","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/jid.2012.129","article-title":"Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance","volume":"132","author":"Jagielska","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib42","doi-asserted-by":"crossref","first-page":"41679","DOI":"10.1074\/jbc.M406413200","article-title":"Alternative activation of STAT1 and STAT3 in response to interferon-gamma","volume":"279","author":"Qing","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2025.04.016_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417306","article-title":"Vitiligo: pathogenesis and new and emerging treatments","volume":"24","author":"Perez-Bootello","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2025.04.016_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111429","article-title":"Role of cytokines in vitiligo: pathogenesis and possible targets for old and new treatments","volume":"22","author":"Custurone","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2025.04.016_bib46","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1073\/pnas.1304988111","article-title":"IFN-\u03b3 signaling maintains skin pigmentation homeostasis through regulation of melanosome maturation","volume":"111","author":"Natarajan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2025.04.016_bib47","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0002-9440(10)63151-3","article-title":"Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model","volume":"164","author":"Ito","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaci.2025.04.016_bib48","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib49","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5693572","article-title":"Increased serum levels of IFN-\u03b3, IL-1\u03b2, and IL-6 in patients with alopecia areata and nonsegmental vitiligo","volume":"2020","author":"Tomaszewska","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jaci.2025.04.016_bib51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1523-1747.2000.00828.x","article-title":"Role of cytotoxic T cells in chronic alopecia areata","volume":"114","author":"Bodemer","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(94)90879-6","article-title":"Lesional expression of interferon-gamma in atopic eczema","volume":"343","author":"Grewe","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2025.04.016_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13718","article-title":"Interferon-gamma serum level and immunohistochemical expression of CD8 cells in tissue biopsies in patients with alopecia areata in correlation with trichoscopic findings","volume":"33","author":"Agamia","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2025.04.016_bib54","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2249.1994.tb06114.x","article-title":"Reduced interferon-gamma (IFN-\u03b3) secretion with increased IFN-\u03b3 mRNA expression in atopic dermatitis: evidence for a post-transcriptional defect","volume":"97","author":"Tang","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib55","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaci.2023.07.010","article-title":"The role of Janus kinase signaling in the pathology of atopic dermatitis","volume":"152","author":"Guttman-Yassky","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/3030268","article-title":"IFN-\u03b3 reduces epidermal barrier function by affecting fatty acid composition of ceramide in a mouse atopic dermatitis model","volume":"2019","author":"Kanoh","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jaci.2025.04.016_bib57","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4049\/jimmunol.0903412","article-title":"Cutting edge: the Th1 response inhibits the generation of peripheral regulatory T cells","volume":"184","author":"Caretto","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib59","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1080\/13685538.2020.1806814","article-title":"Levels of TNF-\u03b1, IL-6, IL-17, IL-37 cytokines in patients with active vitiligo","volume":"23","author":"Karag\u00fcn","year":"2020","journal-title":"Aging Male"},{"key":"10.1016\/j.jaci.2025.04.016_bib60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijd.ijd_27_22","article-title":"A cross-sectional study of the levels of cytokines IL-6, TNF-\u03b1, and IFN-\u03b3 in blood and skin (lesional and uninvolved) of vitiligo patients and their possible role as biomarkers","volume":"68","author":"De","year":"2023","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib61","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/ijd.15658","article-title":"IFN-\u03b1 and TNF-\u03b1 serum levels and their association with disease severity in Egyptian children and adults with alopecia areata","volume":"60","author":"Omar","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib62","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/ijt.ijt_47_17","article-title":"Detection of tumor necrosis factor-alpha in nonlesional tissues of alopecia areata patients: a prove for a systemic disease","volume":"9","author":"Gohary","year":"2017","journal-title":"Int J Trichology"},{"key":"10.1016\/j.jaci.2025.04.016_bib63","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/jid.2014.83","article-title":"TNF-\u03b1 and Th2 cytokines induce atopic dermatitis\u2013like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents","volume":"134","author":"Danso","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib64","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40257-013-0039-3","article-title":"The role of tumor necrosis factor-\u03b1 in the pathogenesis of vitiligo","volume":"14","author":"Camara-Lemarroy","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155432","article-title":"Tumor necrosis factor-alpha affects melanocyte survival and melanin synthesis via multiple pathways in vitiligo","volume":"140","author":"Singh","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.jaci.2025.04.016_bib66","article-title":"Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo","volume":"5","author":"Boukhedouni","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2025.04.016_bib67","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jbspin.2011.09.017","article-title":"TNF\u03b1: activator or inhibitor of regulatory T cells?","volume":"79","author":"Biton","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaci.2025.04.016_bib68","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.3390\/cells10123397","article-title":"The role of serum Th1, Th2, and Th17 cytokines in patients with alopecia areata: clinical implications","volume":"10","author":"Wa\u015bkiel-Burnat","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jaci.2025.04.016_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.118317","article-title":"Amygdalin ameliorates alopecia areata on C3H\/HeJ mice by inhibiting inflammation through JAK2\/STAT3 pathway","volume":"331","author":"He","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.jaci.2025.04.016_bib70","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/cod.13955","article-title":"The role of interleukin-1\u03b2 in the immune response to contact allergens","volume":"85","author":"Yeung","year":"2021","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaci.2025.04.016_bib71","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/928030","article-title":"Cytokines and other mediators in alopecia areata","volume":"2010","author":"Gregoriou","year":"2010","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jaci.2025.04.016_bib72","article-title":"Th17 cells and activated dendritic cells are increased in vitiligo lesions","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2025.04.016_bib73","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/jid.2011.306","article-title":"Analysis of gene expression in atopic dermatitis using a microabrasive method","volume":"132","author":"Bianchi","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib74","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/j.1365-2222.2008.02987.x","article-title":"The development of atopic dermatitis is independent of immunoglobulin E up-regulation in the K14-IL-4 SKH1 transgenic mouse model","volume":"38","author":"Chen","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.04.016_bib75","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1468-3083.2011.04133.x","article-title":"The effect of topically applied corticosteroids on interleukin 1\u03b2 levels in patients with atopic dermatitis","volume":"26","author":"Nutan","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2025.04.016_bib76","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/all.13801","article-title":"Spontaneous atopic dermatitis in mice with a defective skin barrier is independent of ILC2 and mediated by IL-1\u03b2","volume":"74","author":"Schwartz","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.04.016_bib77","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2011.12.989","article-title":"Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency","volume":"129","author":"Kezic","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib78","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3390\/ijms23052684","article-title":"Multiple roles for cytokines in atopic dermatitis: from pathogenic mediators to endotype-specific biomarkers to therapeutic targets","volume":"23","author":"Fania","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2025.04.016_bib79","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/path.4887","article-title":"IL-1\u03b2 induces thymic stromal lymphopoietin and an atopic dermatitis-like phenotype in reconstructed healthy human epidermis","volume":"242","author":"Bernard","year":"2017","journal-title":"J Pathol"},{"key":"10.1016\/j.jaci.2025.04.016_bib80","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cyto.2016.12.014","article-title":"Increased systemic and epidermal levels of IL-17A and IL-1\u03b2 promotes progression of non-segmental vitiligo","volume":"91","author":"Bhardwaj","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.jaci.2025.04.016_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107020","article-title":"Association of neuropeptide Y (NPY), interleukin-1B (IL1B) genetic variants and correlation of IL1B transcript levels with vitiligo susceptibility","volume":"9","author":"Laddha","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2025.04.016_bib82","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/ijc.25182","article-title":"Interleukins 1\u03b1 and 1\u03b2 secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens","volume":"127","author":"Kholmanskikh","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jaci.2025.04.016_bib83","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaci.2019.10.036","article-title":"Activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in keratinocytes promotes cutaneous T-cell response in patients with vitiligo","volume":"145","author":"Li","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib85","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/1523-1747.ep12395722","article-title":"Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone","volume":"103","author":"Hoffmann","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib86","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/1523-1747.ep12395398","article-title":"Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene","volume":"103","author":"Tarlow","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib87","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2362.1992.tb01480.x","article-title":"A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro","volume":"22","author":"Pociot","year":"1992","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jaci.2025.04.016_bib88","article-title":"Interleukin-18 and IL-18BP in inflammatory dermatological diseases","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib89","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.jid.2020.12.021","article-title":"The role of CXCL10 and IL-18 as markers of repigmentation response in nonsegmental vitiligo treated with narrowband UVB phototherapy: a prospective cohort study","volume":"141","author":"Hojman","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib90","doi-asserted-by":"crossref","first-page":"29357","DOI":"10.3390\/ijms161226172","article-title":"IL-18 and cutaneous inflammatory diseases","volume":"16","author":"Lee","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2025.04.016_bib91","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000053821","article-title":"Interleukin-18 is elevated in the sera from patients with atopic dermatitis and from atopic dermatitis model mice, NC\/Nga","volume":"125","author":"Tanaka","year":"2001","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib92","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/bjd.17088","article-title":"Systemic and stratum corneum biomarkers of severity in infant atopic dermatitis include markers of innate and T helper cell-related immunity and angiogenesis","volume":"180","author":"McAleer","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib93","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaci.2024.10.027","article-title":"IL-9 sensitizes human TH2 cells to proinflammatory IL-18 signals in atopic dermatitis","volume":"155","author":"Sch\u00e4rli","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib94","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2005.01.030","article-title":"Single nucleotide polymorphisms of the IL18 gene are associated with atopic eczema","volume":"115","author":"Novak","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib95","first-page":"560","article-title":"Interleukin-18 is elevated in the horny layer in patients with atopic dermatitis and is associated with Staphylococcus aureus colonization: elevated IL-18 in the horny layer of patients with AD","volume":"164","author":"Inoue","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib96","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3389\/fimmu.2020.00882","article-title":"Inflammasomes in common immune-related skin diseases","volume":"11","author":"Tang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib98","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1189\/jlb.0603272","article-title":"The main function of IL-2 is to promote the development of T regulatory cells","volume":"74","author":"Malek","year":"2003","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2025.04.016_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib100","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/exd.12918","article-title":"Biomarkers of alopecia areata disease activity and response to corticosteroid treatment","volume":"25","author":"Fuentes-Duculan","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib101","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000486462","article-title":"Serum levels of interleukin-2 in patients with alopecia areata: relationship with clinical type and duration of the disease","volume":"4","author":"Kasumagi\u0107-Halilovic","year":"2018","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.jaci.2025.04.016_bib102","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jocd.12517","article-title":"Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-\u03b1) in vitiligo\u2014new insight into pathogenesis of disease","volume":"18","author":"Sushama","year":"2019","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib103","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0923-1811(98)00070-X","article-title":"Serum concentration of the soluble interleukin-2 receptor in vitiligo patients","volume":"19","author":"Yeo","year":"1999","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2025.04.016_bib104","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4103\/ijd.IJD_300_20","article-title":"The study of serum level of interleukin-2, interleukin-6, and tumor necrosis factor-alpha in stable and progressive vitiligo patients from Sina Hospital in Tabriz, Iran","volume":"66","author":"Ranjkesh","year":"2021","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2025.04.016_bib106","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/BF00918791","article-title":"Interleukin 2 therapy in severe atopic dermatitis","volume":"11","author":"Hsieh","year":"1991","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib107","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/ijt.ijt_80_18","article-title":"Serum interleukin-15 is a marker of alopecia areata severity","volume":"11","author":"Ebrahim","year":"2019","journal-title":"Int J Trichology"},{"key":"10.1016\/j.jaci.2025.04.016_bib108","doi-asserted-by":"crossref","first-page":"904","DOI":"10.5114\/ada.2020.102103","article-title":"Serum level of interleukin-15 in active alopecia areata patients and its relation to age, sex, and disease severity","volume":"37","author":"El Aziz Ragab","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.jaci.2025.04.016_bib109","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5114\/ada.2019.82826","article-title":"Serum concentrations of selected proinflammatory cytokines in children with alopecia areata","volume":"36","author":"Tabara","year":"2019","journal-title":"Adv Dermatol Allergol"},{"key":"10.1016\/j.jaci.2025.04.016_bib110","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/jocd.13908","article-title":"Elevated serum level of interleukin-15 in vitiligo patients and its correlation with disease severity but not activity","volume":"20","author":"Atwa","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib111","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1078-0432.CCR-12-3603","article-title":"Molecular pathways: interleukin-15 signaling in health and in cancer","volume":"20","author":"Mishra","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaci.2025.04.016_bib112","article-title":"Pathophysiology of skin resident memory T cells","volume":"11","author":"Tokura","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib113","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/pcmr.12949","article-title":"An update on vitiligo pathogenesis","volume":"34","author":"Seneschal","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2025.04.016_bib114","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1159\/000508515","article-title":"IL-15 expression pattern in atopic dermatitis","volume":"181","author":"Karlen","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib115","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.jaci.2018.11.031","article-title":"Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib116","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.3390\/jcm11154431","article-title":"The JAK\/STAT pathway and its selective inhibition in the treatment of atopic dermatitis: a systematic review","volume":"11","author":"Tsiogka","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaci.2025.04.016_bib117","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/jid.2012.331","article-title":"IL-4 inhibits the melanogenesis of normal human melanocytes through the JAK2\u2013STAT6 signaling pathway","volume":"133","author":"Choi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib118","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jisp.2020.04.007","article-title":"Alopecia areata: a complex cytokine driven disease","volume":"20","author":"Song","year":"2020","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jaci.2025.04.016_bib119","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/ITT.S260370","article-title":"Targeting IL-4 for the treatment of atopic dermatitis","volume":"9","author":"Chiricozzi","year":"2020","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.jaci.2025.04.016_bib120","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jid.2015.11.007","article-title":"Influence of Th2 cytokines on the cornified envelope, tight junction proteins, and \u03b2-defensins in filaggrin-deficient skin equivalents","volume":"136","author":"H\u00f6nzke","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib121","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.3390\/ijms21155382","article-title":"Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis","volume":"21","author":"Furue","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2025.04.016_bib122","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jaci.2024.06.002","article-title":"Adipose tissue remodeling via TSLP-mediated IL-4\/IL-13 signaling: implications for atopic dermatitis and skin barrier","volume":"154","author":"Sugita","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib124","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib125","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.jaci.2018.06.029","article-title":"An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation","volume":"142","author":"Song","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib126","first-page":"145","article-title":"The evaluation of dupilumab treatment response in atopic dermatitis patients","volume":"8","author":"Askin","year":"2020","journal-title":"North Clin Istanb"},{"key":"10.1016\/j.jaci.2025.04.016_bib127","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jid.2021.09.015","article-title":"Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through Jak signaling","volume":"142","author":"Martins","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib128","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaci.2023.09.021","article-title":"Improvements in immune\/melanocyte biomarkers with JAK3\/TEC family kinase inhibitor ritlecitinib in vitiligo","volume":"153","author":"Guttman-Yassky","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cells12020217","article-title":"Pathogenic Th2 cytokine profile skewing by IFN-\u03b3-responding vitiligo fibroblasts via CCL2\/CCL8","volume":"12","author":"Jin","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jaci.2025.04.016_bib130","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/exd.14254","article-title":"Diphenylcyclopropenone plays an effective therapeutic role by up-regulating the TSLP\/OX40L\/IL-13 pathway in severe alopecia areata","volume":"30","author":"Gong","year":"2021","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib131","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1600-0625.2011.01280.x","article-title":"Regulation of caspase 14 expression in keratinocytes by inflammatory cytokines\u2014a possible link between reduced skin barrier function and inflammation? Caspase 14 in skin inflammation","volume":"20","author":"Hvid","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib132","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib133","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI117408","article-title":"Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis","volume":"94","author":"Hamid","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2025.04.016_bib134","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.3390\/ijms25147598","article-title":"Serum concentration of IL-5 receptor (IL-5R) and associations with disease severity in patients with chronic spontaneous urticaria (CSU) and atopic dermatitis (AD)","volume":"25","author":"Gomu\u0142ka","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2025.04.016_bib135","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1346-8138.2001.tb00124.x","article-title":"Reduction of serum interleukin-5 levels reflect clinical improvement in patients with atopic dermatitis","volume":"28","author":"Kondo","year":"2001","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2024.114259","article-title":"Changes and significance of Th1\/Th2 and Treg\/Th17 cells and their cytokines in patients with alopecia areata","volume":"442","author":"Yang","year":"2024","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jaci.2025.04.016_bib137","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/exd.14129","article-title":"Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata","volume":"29","author":"Ito","year":"2020","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib138","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK\u2013STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib140","first-page":"130","article-title":"Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity","volume":"182","author":"Bain","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib141","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2340\/00015555-1408","article-title":"Inflammed skin harbours Th9 cells","volume":"93","author":"Cortelazzi","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2025.04.016_bib142","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/cei.12198","article-title":"Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis","volume":"175","author":"Ma","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib143","doi-asserted-by":"crossref","first-page":"8569","DOI":"10.3390\/ijms25168569","article-title":"Heterogeneous IL-9 production by circulating skin-tropic and extracutaneous memory T cells in atopic dermatitis patients","volume":"25","author":"Garc\u00eda-Jim\u00e9nez","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2025.04.016_bib144","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jaci.2019.09.031","article-title":"Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood","volume":"145","author":"Czarnowicki","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib145","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2340\/00015555-2643","article-title":"Keratinocyte proliferation and differentiation on IL-9 stimulation: an explorative in vitro study","volume":"97","author":"Niehues","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2025.04.016_bib146","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1525-1470.2012.01766.x","article-title":"Serum interleukin-9 levels are associated with clinical severity in children with atopic dermatitis","volume":"30","author":"Ciprandi","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib147","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1111\/all.16225","article-title":"Evolution of pathologic B-cell subsets and serum environment-specific sIgEs in patients with atopic dermatitis and controls, from infancy to adulthood","volume":"79","author":"Czarnowicki","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.04.016_bib148","first-page":"16","article-title":"An association between IL-9 and IL-9 receptor gene polymorphisms and atopic dermatitis in a Korean population","volume":"62","author":"Namkung","year":"2011","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2025.04.016_bib149","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00281-016-0607-8","article-title":"TH9 cells in skin disorders","volume":"39","author":"Clark","year":"2017","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaci.2025.04.016_bib150","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ni.1659","article-title":"Transforming growth factor-\u03b2 \u201creprograms\u201d the differentiation of T helper 2 cells and promotes an interleukin 9\u2013producing subset","volume":"9","author":"Veldhoen","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib151","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.immuni.2010.07.014","article-title":"Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells","volume":"33","author":"Staudt","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2025.04.016_bib152","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/pcmr.12978","article-title":"Presence and the roles of IL-9\/Th9 axis in vitiligo","volume":"34","author":"Kumar","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2025.04.016_bib153","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/09546634.2020.1752887","article-title":"Therapeutic outcome of diphencyprone and its correlation with serum cytokine profile in alopecia areata","volume":"33","author":"Manimaran","year":"2022","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaci.2025.04.016_bib154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2019.01.013","article-title":"Clinical significance and immunobiology of IL-21 in autoimmunity","volume":"99","author":"Long","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaci.2025.04.016_bib155","doi-asserted-by":"crossref","first-page":"34605","DOI":"10.1074\/jbc.M705100200","article-title":"IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner","volume":"282","author":"Wei","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2025.04.016_bib156","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.4049\/jimmunol.180.3.1800","article-title":"Autocrine regulation of IL-21 production in human T lymphocytes","volume":"180","author":"Caprioli","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib157","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1111\/all.14845","article-title":"High-dimensional analysis defines multicytokine T-cell subsets and supports a role for IL-21 in atopic dermatitis","volume":"76","author":"Czarnowicki","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.04.016_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102689","article-title":"New developments implicating IL-21 in autoimmune disease","volume":"122","author":"Ren","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaci.2025.04.016_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250075","article-title":"Interleukin-21 in autoimmune and inflammatory skin diseases","volume":"53","author":"Mesas-Fern\u00e1ndez","year":"2023","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib160","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3892\/br.2013.166","article-title":"The emerging role of interleukin-21 in allergic diseases (Review)","volume":"1","author":"Gong","year":"2013","journal-title":"Biomed Rep"},{"key":"10.1016\/j.jaci.2025.04.016_bib161","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.0105-2896.2004.00201.x","article-title":"Biology of IL-21 and the IL-21 receptor","volume":"202","author":"Mehta","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2025.04.016_bib162","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.4049\/jimmunol.0803009","article-title":"IL-21: an executor of B cell fate","volume":"182","author":"Konforte","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib163","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190472","article-title":"IL-21 is a broad negative regulator of IgE class switch recombination in mouse and human B cells","volume":"217","author":"Yang","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2025.04.016_bib164","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3389\/fimmu.2019.01865","article-title":"IL-21 induces an imbalance of Th17\/Treg cells in moderate-to-severe plaque psoriasis patients","volume":"10","author":"Shi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1211620","article-title":"IL-21 is required for the maintenance and pathogenesis of murine V\u03b34+ IL-17-producing \u03b3\u03b4T cells","volume":"14","author":"Ishikawa","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib166","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1073\/pnas.1301138111","article-title":"Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression","volume":"111","author":"Liao","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2025.04.016_bib167","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1182\/blood-2011-10-388546","article-title":"IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis","volume":"119","author":"Attridge","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2025.04.016_bib168","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/ijd.12808","article-title":"T-helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor-\u03b1) in patients with alopecia areata: association with clinical type and severity","volume":"55","author":"Atwa","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib169","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/jid.2011.377","article-title":"IFN-\u03b3, IL-21, and IL-10 co-expression in evolving autoimmune vitiligo lesions of Smyth line chickens","volume":"132","author":"Shi","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib170","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.alit.2016.10.010","article-title":"Serum IL-21 levels are elevated in atopic dermatitis patients with acute skin lesions","volume":"66","author":"Mizutani","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2025.04.016_bib171","first-page":"47","article-title":"IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice","volume":"119","author":"Jin","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2025.04.016_bib172","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/pcmr.12355","article-title":"Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development","volume":"28","author":"Zhou","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2025.04.016_bib173","doi-asserted-by":"crossref","first-page":"1","DOI":"10.24966\/CDT-8771\/100039","article-title":"Correlation between vitamin D and interleukin-21 in patients with vitiligo","volume":"5","author":"Mohamed Amer","year":"2019","journal-title":"Clin Dermatol Ther"},{"key":"10.1016\/j.jaci.2025.04.016_bib174","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2172-13-18","article-title":"Understanding mechanisms of vitiligo development in Smyth line of chickens by transcriptomic microarray analysis of evolving autoimmune lesions","volume":"13","author":"Shi","year":"2012","journal-title":"BMC Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib175","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nri1148","article-title":"Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?","volume":"3","author":"Croft","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib176","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.4049\/jimmunol.161.12.6510","article-title":"Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses","volume":"161","author":"Gramaglia","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib177","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40257-023-00838-9","article-title":"OX40 in the pathogenesis of atopic dermatitis\u2014a new therapeutic target","volume":"25","author":"Croft","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib178","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jid.2022.11.009","article-title":"Diverse role of OX40 on T cells as a therapeutic target for skin diseases","volume":"143","author":"Iriki","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib179","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1084\/jem.20051135","article-title":"TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand","volume":"202","author":"Ito","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2025.04.016_bib180","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2025.04.016_bib181","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1038\/s41467-020-17293-3","article-title":"Th1 responses in vivo require cell-specific provision of OX40L dictated by environmental cues","volume":"11","author":"Gajdasik","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.04.016_bib182","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.immuni.2018.05.003","article-title":"Tissue-restricted adaptive type 2 immunity is orchestrated by expression of the costimulatory molecule OX40L on group 2 innate lymphoid cells","volume":"48","author":"Halim","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2025.04.016_bib183","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev-immunol-030409-101243","article-title":"Control of immunity by the TNFR-related molecule OX40 (CD134)","volume":"28","author":"Croft","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib184","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1111\/j.1468-3083.2012.04587.x","article-title":"OX40 ligand and OX40 are increased in atopic dermatitis lesions but do not correlate with clinical severity","volume":"27","author":"Ilves","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2025.04.016_bib185","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3452","article-title":"The OX40 axis is associated with both systemic and local involvement in atopic dermatitis","volume":"100","author":"Elsner","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2025.04.016_bib186","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/eji.201041033","article-title":"IL-33-activated dendritic cells are critical for allergic airway inflammation","volume":"41","author":"Besnard","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib187","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib188","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41423-019-0291-4","article-title":"Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders","volume":"17","author":"Chen","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib189","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094260","article-title":"Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata","volume":"9","author":"Bertolini","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2025.04.016_bib190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.imlet.2006.04.001","article-title":"Functional characterization of OX40 expressed on human CD8+ T cells","volume":"106","author":"Fujita","year":"2006","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jaci.2025.04.016_bib191","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/cup.13479","article-title":"Regulatory T-cells in alopecia areata","volume":"46","author":"Speiser","year":"2019","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaci.2025.04.016_bib192","author":"Gay-Mimbrera"},{"key":"10.1016\/j.jaci.2025.04.016_bib193","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2568","article-title":"Sensing and alarm function of resident memory CD8+ T cells","volume":"14","author":"Schenkel","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib194","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/bjd\/ljad303","article-title":"Resident cutaneous memory T cells: a clinical review of their role in chronic inflammatory dermatoses and potential as therapeutic targets","volume":"189","author":"Pham","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib195","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1084\/jem.20032177","article-title":"A skin-selective homing mechanism for human immune surveillance T cells","volume":"199","author":"Schaerli","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2025.04.016_bib196","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010641","article-title":"Resident memory T cells in human health and disease","volume":"7","author":"Clark","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2025.04.016_bib197","doi-asserted-by":"crossref","first-page":"19739","DOI":"10.1073\/pnas.1208927109","article-title":"Tissue-resident memory CD8+ T cells continuously patrol skin epithelia to quickly recognize local antigen","volume":"109","author":"Ariotti","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2025.04.016_bib198","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/all.13223","article-title":"Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues","volume":"72","author":"Brunner","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.04.016_bib199","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jid.2016.02.074","article-title":"Multicytokine-producing tissue resident memory (TRM) cells in atopic dermatitis patient [Abstract 049]","volume":"136","author":"Kim","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib200","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jid.2018.03.026","article-title":"Distinct transcriptome signature of skin-resident memory T cells and migratory memory T cells in atopic dermatitis [Abstract 022]","volume":"138","author":"Kim","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib201","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaci.2023.11.017","article-title":"Resident memory T cells in nonlesional skin and healed lesions of patients with chronic inflammatory diseases: appearances can be deceptive","volume":"153","author":"Migayron","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib202","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2006.09.004","article-title":"Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy","volume":"56","author":"Nicolaidou","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib203","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/jid.2014.527","article-title":"Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study","volume":"135","author":"Cavali\u00e9","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib204","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3","volume":"138","author":"Boniface","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib205","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jid.2018.10.032","article-title":"Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo","volume":"139","author":"Richmond","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib206","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.1900027","article-title":"The role of memory CD8+ T cells in vitiligo","volume":"203","author":"Riding","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib207","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.4049\/jimmunol.1502337","article-title":"IL-15-independent maintenance of tissue-resident and boosted effector memory CD8 T cells","volume":"196","author":"Schenkel","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib208","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2025.04.016_bib209","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.19040","article-title":"Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing","volume":"183","author":"Del Duca","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib210","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.jid.2024.01.006","article-title":"Increase in CD8+ effector memory T cells re-expressing CD45RA correlates with intractability of severe alopecia areata","volume":"144","author":"Takahashi","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib211","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2025.04.016_bib212","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jid.2020.06.013","article-title":"The possible linkage of granzyme B-producing skin T cells with the disease prognosis of alopecia areata","volume":"141","author":"Koguchi-Yoshioka","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib213","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/s41590-023-01547-5","article-title":"A virtual memory CD8+ T cell-originated subset causes alopecia areata through innate-like cytotoxicity","volume":"24","author":"Seok","year":"2023","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib214","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib215","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2025.04.016_bib216","first-page":"2120","article-title":"FDA approves tofacitinib for rheumatoid arthritis","volume":"69","author":"Traynor","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jaci.2025.04.016_bib217","article-title":"FDA approves ruxolitinib (Opzelura) for vitiligo therapy: a breakthrough in the field of dermatology","volume":"81","author":"Sheikh","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.jaci.2025.04.016_bib218","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.04.016_bib219","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2025.04.016_bib220","article-title":"Olumniant (Baricitinib) oral tablets: an insight into FDA-approved systemic treatment for alopecia areata","volume":"80","author":"Ali","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.jaci.2025.04.016_bib221","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40257-022-00684-1","article-title":"Baricitinib: a review in moderate to severe atopic dermatitis","volume":"23","author":"Hoy","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.annder.2024.103300","article-title":"Vitiligo treated with oral baricitinib and heliotherapy: a case series","volume":"151","author":"Reviron","year":"2024","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaci.2025.04.016_bib223","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1111\/jdv.20109","article-title":"Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid-resistant vitiligo: a prospective case series","volume":"39","author":"Zhu","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2025.04.016_bib224","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/CCID.S396430","article-title":"Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB-UVB phototherapy","volume":"16","author":"Li","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib225","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/jcph.1360","article-title":"Systemic tofacitinib concentrations in adult patients with atopic dermatitis treated with 2% tofacitinib ointment and application to pediatric study planning","volume":"59","author":"Purohit","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2025.04.016_bib226","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/10600280221096713","article-title":"Abrocitinib: a new FDA-approved drug for moderate-to-severe atopic dermatitis","volume":"57","author":"Perche","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaci.2025.04.016_bib227","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaad.2024.09.025","article-title":"Oral abrocitinib for treatment of refractory alopecia areata: a retrospective study","volume":"92","author":"Zhang","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib228","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2242706","article-title":"Successful treatment of alopecia universalis with abrocitinib: a case report","volume":"34","author":"Zhang","year":"2023","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaci.2025.04.016_bib229","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/jocd.15896","article-title":"Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib","volume":"23","author":"Huang","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib230","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/JAA.S458684","article-title":"Abrocitinib improved dupilumab-resistant severe atopic dermatitis with comorbid mild alopecia areata in a 12-year-old boy: a case report with 1-year follow-up","volume":"17","author":"Liu","year":"2024","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2025.04.016_bib231","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/ajd.13836","article-title":"Successful treatment of chronic severe alopecia areata with abrocitinib","volume":"63","author":"Bennett","year":"2022","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib232","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2022.02.027","article-title":"A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib","volume":"22","author":"Zhao","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaci.2025.04.016_bib233","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jaad.2024.05.078","article-title":"A prospective observational study of oral abrocitinib and narrow-band ultraviolet-B in refractory progressive vitiligo","volume":"91","author":"Xu","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib234","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","article-title":"Ritlecitinib: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2025.04.016_bib235","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1111\/jdv.18906","article-title":"Apremilast 30 mg twice daily combined with dupilumab for the treatment of recalcitrant moderate-to-severe atopic dermatitis","volume":"37","author":"Cunningham","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2025.04.016_bib236","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jid.2018.10.043","article-title":"A phase 2 randomized trial of apremilast in patients with atopic dermatitis","volume":"139","author":"Simpson","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib237","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1111\/jocd.15903","article-title":"The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: network meta-analyses of clinical trials","volume":"22","author":"Gupta","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib238","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.autrev.2011.05.004","article-title":"Human FoxP3+ regulatory T cells in systemic autoimmune diseases","volume":"10","author":"Miyara","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2025.04.016_bib239","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ni1428","article-title":"Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice","volume":"8","author":"Kim","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib240","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.4049\/jimmunol.178.7.4062","article-title":"Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells","volume":"178","author":"Bayer","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib241","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/1744666X.2016.1199957","article-title":"Restoring regulation\u2014IL-2 therapy in systemic lupus erythematosus","volume":"12","author":"Humrich","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2025.04.016_bib242","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrrheum.2014.105","article-title":"TREG-cell therapies for autoimmune rheumatic diseases","volume":"10","author":"Miyara","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib243","doi-asserted-by":"crossref","first-page":"9230","DOI":"10.1038\/s41467-024-53384-1","article-title":"The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials","volume":"15","author":"Silverberg","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.04.016_bib244","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib245","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib246","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jdcr.2023.03.025","article-title":"Vitiligo during dupilumab therapy","volume":"36","author":"Picone","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaci.2025.04.016_bib247","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1111\/jdv.19132","article-title":"Vitiligo induced by dupilumab treatment: a case series","volume":"37","author":"Ren","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2025.04.016_bib248","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/1346-8138.16764","article-title":"Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: a retrospective study","volume":"50","author":"Napolitano","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib249","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-IL-4R\u03b1) for alopecia areata patients","volume":"77","author":"Guttman-Yassky","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.04.016_bib250","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00403-024-03225-4","article-title":"Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study","volume":"316","author":"David","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2025.04.016_bib251","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2312245","article-title":"Dupilumab therapy for alopecia areata: a case series and review of the literature","volume":"35","author":"Huang","year":"2024","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaci.2025.04.016_bib252","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1111\/jocd.15136","article-title":"Dupilumab for alopecia areata treatment: a double-edged sword?","volume":"21","author":"Jin","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib253","first-page":"1","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis in adults","volume":"28","author":"Abduelmula","year":"2023","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.jaci.2025.04.016_bib254","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/ijd.17010","article-title":"Tralokinumab as a therapeutic option for patients with concurrent atopic dermatitis and alopecia areata","volume":"63","author":"Tavoletti","year":"2024","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib256","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2025.04.016_bib257","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1111\/1346-8138.17023","article-title":"A case of atopic dermatitis with self-healing acute diffuse and total alopecia during nemolizumab treatment","volume":"51","author":"Suehiro","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib258","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bjd\/ljad240","article-title":"Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial","volume":"189","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.04.016_bib259","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Guttman-Yassky","year":"2023","journal-title":"Lancet"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925004567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925004567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:32:51Z","timestamp":1778142771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674925004567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":257,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0091674925004567"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2025.04.016","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Converging paths toward unified therapeutic approaches in atopic dermatitis, vitiligo, and alopecia areata","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2025.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}